Litronesib_LCMS_19488_MedChemExpress
MK-6892_LCMS_09617_MedChemExpress
=====================================================================Acq. Operator : Li Shan(LCMS-02) Seq. Line : 27Acq. Instrument : HY-LCMS-02 Location : P1-C-07Injection Date : 7/13/2015 11:22:26 AM Inj : 1Inj Volume : 3.000 µlAcq. Method : D:\AGLIENT 1260\DATA\20150713\20150713 2015-07-13 09-29-38\100-1000MS+3MIN- 1.5_(0.02%FA).MLast changed : 7/13/2015 9:29:38 AM by Li Shan(LCMS-02)Analysis Method : D:\AGLIENT 1260\DATA\20150709\20150709 2015-07-09 09-04-13\100-1000MS+3MIN- 1.5_(0.02%FA).M (Sequence Method)Last changed : 7/13/2015 1:24:17 PM by Li Shan(LCMS-02) (modified after loading)Method Info : Postive,MS:100-1000,Column ID:A-RP-132,40℃Catalog No : HY-10680 Batch#09617 A-RP-134Additional Info : Peak(s) manually integratedmin0.511.52 2.53mAU 020040060080010001200 DAD1 C, Sig=254,4 Ref=off (D:\AGLIENT...0\DATA\20150713\20150713 2015-07-13 09-29-38\CPK2015-713-09617.D)1.5911.803 1.8612.0562.341===================================================================== Area Percent Report =====================================================================Sorted By : Signal Multiplier : 1.0000Dilution : 1.0000Do not use Multiplier & Dilution Factor with ISTDsSignal 1: DAD1 C, Sig=254,4 Ref=offPeak RetTime Type Width Area Height Area # [min] [min] [mAU*s] [mAU] %----|-------|----|-------|----------|----------|--------| 1 1.591 MM 0.0429 8.83071 3.43181 0.2371 2 1.803 MF 0.0233 3.17571 2.26929 0.0853 3 1.861 FM 0.0482 21.20513 7.33550 0.5693 4 2.056 MM 0.0433 3690.43457 1420.24146 99.0709 5 2.341 MM 0.0624 1.39770 3.73493e-1 0.0375Totals : 3725.04381 1433.65154===================================================================== *** End of Report ***=====================================================================Acq. Operator : Li Shan(LCMS-02) Seq. Line : 27Acq. Instrument : HY-LCMS-02 Location : P1-C-07Injection Date : 7/13/2015 11:22:26 AM Inj : 1Inj Volume : 3.000 µlAcq. Method : D:\AGLIENT 1260\DATA\20150713\20150713 2015-07-13 09-29-38\100-1000MS+3MIN- 1.5_(0.02%FA).MLast changed : 7/13/2015 9:29:38 AM by Li Shan(LCMS-02)Analysis Method : D:\AGLIENT 1260\DATA\20150709\20150709 2015-07-09 09-04-13\100-1000MS+3MIN- 1.5_(0.02%FA).M (Sequence Method)Last changed : 7/13/2015 1:25:31 PM by Li Shan(LCMS-02) (modified after loading)Method Info : Postive,MS:100-1000,Column ID:A-RP-132,40℃Catalog No : HY-10680 Batch#09617 A-RP-134Additional Info : Peak(s) manually integratedmin0.511.522.53100000200000300000400000500000600000 MSD1 TIC, MS File (D:\AGLIENT 1260\DATA\20150713\20150713 2015-07-13 09-29-38\CPK2015-713-09617.D) ES-API, Pos, Sc2.061MS Signal: MSD1 TIC, MS File, ES-API, Pos, Scan, Frag: 50 Spectra averaged over upper half of peaks. Noise Cutoff: 1000 counts.Reportable Ion Abundance: > 10%.Retention Mol. Weight Time (MS) MS Area or Ion2.061 3087828 344.10 I 343.10 Im/z10020030040050060070080020406080100*MSD1 SPC, time=2.035:2.090 of D:\AGLIENT 1260\DATA\20150713\20150713 2015-07-13 09-29-38\CPK2015-713-09617.D ES-API Max: 358640387.1344.1 343.1*** End of Report ***。
marked manuscript
Quality evaluation of Flos Lonicerae through a simultaneous determination of seven saponins by HPLC with ELSDXing-Yun Chai1, Song-Lin Li2, Ping Li1*1Key Laboratory of Modern Chinese Medicines and Department of Pharmacognosy, China Pharmaceutical University, Nanjing, 210009, People’s Republic of China2Institute of Nanjing Military Command for Drug Control, Nanjing, 210002, People’s Republic of China*Corresponding author: Ping LiKey Laboratory of Modern Chinese Medicines and Department of Pharmacognosy, China Pharmaceutical University, Nanjing 210009, People’s Republic of China.E-mail address: lipingli@Tel.: +86-25-8324-2299; 8539-1244; 135********Fax: +86-25-8532-2747AbstractA new HPLC coupled with evaporative light scattering detection (ELSD) method has been developed for the simultaneous quantitative determination of seven major saponins, namely macranthoidinB (1), macranthoidin A (2), dipsacoside B (3), hederagenin-28-O-β-D-glucopyranosyl(6→1)-O-β-D- glucopyranosyl ester (4), macranthoside B (5), macranthoside A (6), and hederagenin-3-O-α-L-arabinopyranosyl(2→1)-O-α-L-rhamnopyranoside (7)in Flos Lonicerae, a commonly used traditional Chinese medicine (TCM) herb.Simultaneous separation of these seven saponins was achieved on a C18 analytical column with a mixed mobile phase consisting of acetonitrile(A)-water(B)(29:71 v/v) acidified with 0.5% acetic acid. The elution was operated from keeping 29%A for 10min, then gradually to 54%B from 10 to 25 min on linear gradient, and then keep isocratic elution with 54%B from 25 to 30min.The drift tube temperature of ELSD was set at 106℃, and with the nitrogen flow-rate of 2.6 l/min. All calibration curves showed good linear regression (r2 0.9922) within test ranges. This method showed good reproducibility for the quantification of these seven saponins in Flos Lonicerae with intra- and inter-day variations of less than 3.0% and 6.0% respectively. The validated method was successfully applied to quantify seven saponins in five sources of Flos Lonicerae, which provides a new basis of overall assessment on quality of Flos Lonicerae.Keywords: HPLC-ELSD; Flos Lonicerae; Saponins; Quantification1. IntroductionFlos Lonicerae (Jinyinhua in Chinese), the dried buds of several species of the genus Lonicera (Caprifoliaceae), is a commonly used traditional Chinese medicine (TCM) herb. It has been used for centuries in TCM practice for the treatment of sores, carbuncles, furuncles, swelling and affections caused by exopathogenic wind-heat or epidemic febrile diseases at the early stage [1]. Though four species of Lonicera are documented as the sources of Flos Lonicerae in China Pharmacopeia (2000 edition), i.e. L. japonica, L. hypoglauca,L. daystyla and L. confusa, other species such as L. similes and L. macranthoides have also been used on the same purpose in some local areas in China [2]. So it is an important issue to comprehensively evaluate the different sources of Flos Lonicerae, so as to ensure the clinical efficacy of this Chinese herbal drug.Chemical and pharmacological investigations on Flos Lonicerae resulted in discovering several kinds of bioactive components, i.e. chlorogenic acid and its analogues, flavonoids, iridoid glucosides and triterpenoid saponins [3]. Previously, chlorogenic acid has been used as the chemical marker for the quality evaluation of Flos Lonicerae,owing to its antipyretic and antibiotic property as well as its high content in the herb. But this compound is not a characteristic component of Flos Lonicerae, as it has also been used as the chemical marker for other Chinese herbal drugs such as Flos Chrysanthemi and so on[4-5]. Moreover, chlorogenic acid alone could not be responsible for the overall pharmacological activities of Flos Lonicerae[6].On the other hand, many studies revealed that triterpenoidal saponins of Flos Lonicerae possess protection effects on hepatic injury caused by Acetaminophen, Cd, and CCl4, and conspicuous depressant effects on swelling of ear croton oil [7-11]. Therefore, saponins should also be considered as one of the markers for quality control of Flos Lonicerae. Consequently, determinations of all types of components such as chlorogenic acid, flavonoids, iridoid glucosides and triterpenoidal saponins in Flos Lonicerae could be a better strategy for the comprehensive quality evaluation of Flos Lonicerae.Recently an HPLC-ELSD method has been established in our laboratory for qualitative and quantitative determination of iridoid glucosides in Flos Lonicerae [12]. But no method was reported for the determination of triterpenoidal saponins in Flos Lonicera. As a series studies on the comprehensive evaluation of Flos Lonicera, we report here, for the first time, the development of an HPLC-ELSD method for simultaneous determination of seven triterpenoidal saponins in the Chinese herbal drug Flos Lonicerae, i.e.macranthoidin B (1), macranthoidin A (2), dipsacoside B (3), hederagenin-28-O-β-D-glucopyranosyl(6→1)-O-β-D- glucopyranosyl ester (4), macranthoside B (5), macranthoside A (6), and hederagenin-3-O-α-L-arabinopyranosyl(2→1)-O-α-L-rhamnopyranoside (7) (Fig. 1).2. Experimental2.1. Samples, chemicals and reagentsFive samples of Lonicera species,L. japonica from Mi county, HeNan province (LJ1999-07), L. hypoglauca from Jiujang county, JiangXi province (LH2001-06), L. similes from Fei county, ShanDong province (LS2001-07), L. confuse from Xupu county, HuNan province (LC2001-07), and L. macranthoides from Longhu county, HuNan province (LM2000-06) respectively, were collected in China. All samples were authenticated by Dr. Ping Li, professor of department of Pharmacognosy, China Pharmaceutical University, Nanjing, China. The voucher specimens were deposited in the department of Pharmacognosy, China Pharmaceutical University, Nanjing, China. Seven saponin reference compounds: macranthoidin B (1), macranthoidin A (2), dipsacoside B (3), hederagenin-28-O-β-D-glucopyranosyl(6→1)-O-β-D- glucopyranosyl ester (4), macranthoside B (5), macranthoside A (6), and hederagenin-3-O-α-L-arabinopyranosyl(2→1)-O-α-L-rhamnopyranoside (7) were isolated previously from the dried buds of L. confusa by repeated silica gel, sephadex LH-20 and Rp-18 silica gel column chromatography, their structures were elucidated by comparison of their spectral data (UV, IR, MS, 1H- NMR and 13C-NMR) with references [13-15]. The purity of these saponins were determined to be more than 98% by normalization of the peak areas detected by HPLC with ELSD, and showed very stable in methanol solution.HPLC-grade acetonitrile from Merck (Darmstadt, Germany), the deionized water from Robust (Guangzhou, China), were purchased. The other solvents, purchased from Nanjing Chemical Factory (Nanjing, China) were of analytical grade.2.2. Apparatus and chromatographic conditionsAglient1100 series HPLC apparatus was used. Chromatography was carried out on an Aglient Zorbax SB-C18 column（250 4.6mm, 5.0µm）at a column temperature of 25℃.A Rheodyne 7125i sampling valve (Cotati, USA) equipped with a sample loop of 20µl was used for sample injection. The analog signal from Alltech ELSD 2000 (Alltech, Deerfield, IL, USA)was transmitted to a HP Chemstation for processing through an Agilent 35900E (Agilent Technologies, USA).The optimum resolution was obtained by using a linear gradient elution. The mobile phase was composed of acetonitrile(A) and water(B) which acidified with 0.5% acetic acid. The elution was operated from keeping 29%A for 10min, then gradually to 54%B from 10 to 25 min in linear gradient, and back to the isocratic elution of 54%B from 25 to 30 min.The drift tube temperature for ELSD was set at 106℃and the nitrogen flow-rate was of 2.6 l/min. The chromatographic peaks were identified by comparing their retention time with that of each reference compound tried under the same chromatographic conditions with a series of mobile phases. In addition, spiking samples with the reference compounds further confirmed the identities of the peaks.2.3. Calibration curvesMethanol stock solutions containing seven analytes were prepared and diluted to appropriate concentration for the construction of calibration curves. Six concentrationof the seven analytes’ solution were injected in triplicate, and then the calibration curves were constructed by plotting the peak areas versus the concentration of each analyte. The results were demonstrated in Table1.2.4. Limits of detection and quantificationMethanol stock solution containing seven reference compounds were diluted to a series of appropriate concentrations with methanol, and an aliquot of the diluted solutions were injected into HPLC for analysis.The limits of detection (LOD) and quantification (LOQ) under the present chromatographic conditions were determined at a signal-to-noise ratio (S/N) of 3 and 10, respectively. LOD and LOQ for each compound were shown in Table1.2.5. Precision and accuracyIntra- and inter-day variations were chosen to determine the precision of the developed assay. Approximate 2.0g of the pulverized samples of L. macranthoides were weighted, extracted and analyzed as described in 2.6 Sample preparation section. For intra-day variability test, the samples were analyzed in triplicate for three times within one day, while for inter-day variability test, the samples were examined in triplicate for consecutive three days. Variations were expressed by the relative standard deviations. The results were given in Table 2.Recovery test was used to evaluate the accuracy of this method. Accurate amounts of seven saponins were added to approximate 1.0g of L. macranthoides,and then extracted and analyzed as described in 2.6 Sample preparation section. The average recoveries were counted by the formula: recovery (%) = (amount found –original amount)/ amount spiked ×100%, and RSD (%) = (SD/mean) ×100%. The results were given in Table 3.2.6. Sample preparationSamples of Flos Lonicerae were dried at 50℃until constant weight. Approximate 2.0g of the pulverized samples, accurately weighed, was extracted with 60% ethanol in a flask for 4h. The ethanol was evaporated to dryness with a rotary evaporator. Residue was dissolved in water, followed by defatting with 60ml of petroleum ether for 2 times, and then the water solution was evaporated, residue was dissolved with methanol into a 25ml flask. One ml of the methanol solution was drawn and transferred to a 5ml flask, diluted to the mark with methanol. The resultant solution was at last filtrated through a 0.45µm syringe filter (Type Millex-HA, Millipore, USA) and 20µl of the filtrate was injected to HPLC system. The contents of the analytes were determined from the corresponding calibration curves.3. Results and discussionsThe temperature of drift tube and the gas flow-rate are two most important adjustable parameters for ELSD, they play a prominent role to an analyte response. In ourprevious work [12], the temperature of drift tube was optimized at 90°C for the determination of iridoids. As the polarity of saponins are higher than that of iridoids, more water was used in the mobile phase for the separation of saponins, therefore the temperature for saponins determination was optimized systematically from 95°C to 110°C, the flow-rate from 2.2 to 3.0 l/min. Dipsacoside B was selected as the testing saponin for optimizing ELSD conditions, as it was contained in all samples. Eventually, the drift tube temperature of 106℃and a gas flow of 2.6 l/min were optimized to detect the analytes. And these two exact experimental parameters should be strictly controlled in the analytical procedure [16].All calibration curves showed good linear regression (r2 0.9922) within test ranges. Validation studies of this method proved that this assay has good reproducibility. As shown in Table 2, the overall intra- and inter-day variations are less than 6% for all seven analytes. As demonstrated in Table 3, the developed analytical method has good accuracy with the overall recovery of high than 96% for the analytes concerned. The limit of detection (S/N=3) and the limit of quantification (S/N=10) are less than 0.26μg and 0.88μg respectively (Table1), indicating that this HPLC-ELSD method is precise, accurate and se nsitive enough for the quantitative evaluation of major non- chromaphoric saponins in Flos Lonicerae.It has been reported that there are two major types of saponins in Flos Lonicerae, i.e. saponins with hederagenin as aglycone and saponins with oleanolic acid as the aglycone [17]. But hederagenin type saponins of the herb were reported to have distinct activities of liver protection and anti-inflammatory [7-11]. So we adoptedseven hederagenin type saponins as representative markers to establish a quality control method.The newly established HPLC-ELSD method was applied to analyze seven analytes in five plant sources of Flos Lonicerae, i.e. L. japonica,L. hypoglauca,L. confusa,L. similes and L. macranthoides(Table 4). It was found that there were remarkable differences of seven saponins contents between different plant sources of Flos Lonicerae. All seven saponins analyzed could be detected in L. confusa and L. hypoglauca, while only dipsacoside B was detected in L. japonica. Among all seven saponins interested, only dipsacoside B was found in all five plant species of Flos Lonicerae analyzed, and this compound was determined as the major saponin with content of 53.7 mg/g in L. hypoglauca. On the other hand, macranthoidin B was found to be the major saponin with the content higher than 41.0mg/g in L. macranthoides,L. confusa, and L. similis, while the contents of other analytes were much lower.In our previous study [12], overall HPLC profiles of iridoid glucosides was used to qualitatively and quantitatively distinguish different origins of Flos Lonicerae. As shown in Fig.2, the chromatogram profiles of L. confusa, L. japonica and L. similes seem to be similar, resulting in the difficulty of clarifying the origins of Flos Lonicerae solely by HPLC profiles of saponins, in addition to the clear difference of the HPLC profiles of saponins from L. macranthoides and L. hypoglauca.Therefore, in addition to the conventional morphological and histological identification methods, the contents and the HPLC profiles of saponins and iridoids could also be used as accessory chemical evidence toclarify the botanical origin and comprehensive quality evaluation of Flos Lonicerae.4. ConclusionsThis is the first report on validation of an analytical method for qualification and quantification of saponins in Flos Lonicerae. This newly established HPLC-ELSD method can be used to simultaneously quantify seven saponins, i.e. macranthoidin B, macranthoidin A, dipsacoside B, hederagenin-28-O-β-D-glucopyranosyl(6→1)-O-β-D- glucopyranosyl ester, macranthoside B, macranthoside A, and hederagenin-3-O-α-L-arabinopyranosyl(2→1)-O-α-L-rhamnopyranoside in Flos Lonicerae. Together with the HPLC profiles of iridoids, the HPLC-ELSD profiles of saponins could also be used as an accessory chemical evidence to clarify the botanical origin and comprehensive quality evaluation of Flos Lonicerae.AcknowledgementsThis project is financially supported by Fund for Distinguished Chinese Young Scholars of the National Science Foundation of China (30325046) and the National High Tech Program（2003AA2Z2010）.[1]Ministry of Public Health of the People’s Republic of China, Pharmacopoeia ofthe People’s Republic of China, V ol.1, 2000, p. 177.[2]W. Shi, R.B. Shi, Y.R. Lu, Chin. Pharm. J., 34(1999) 724.[3]J.B. Xing, P. Li, D.L. Wen, Chin. Med. Mater., 26(2001) 457.[4]Y.Q. Zhang, L.C. Xu, L.P. Wang, J. Chin. Med. Mater., 21(1996) 204.[5] D. Zhang, Z.W. Li, Y. Jiang, J. Pharm. Anal., 16(1996) 83.[6]T.Z. Wang, Y.M. Li, Huaxiyaoxue Zazhi, 15(2000) 292.[7]J.ZH. Shi, G.T. Liu. Acta Pharm. Sin., 30(1995) 311.[8]Y. P. Liu, J. Liu, X.SH. Jia, et al. Acta Pharmacol. Sin., 13 (1992) 209.[9]Y. P. Liu, J. Liu, X.SH. Jia, et al. Acta Pharmacol. Sin., 13 (1992) 213.[10]J.ZH. Shi, L. Wan, X.F. Chen.ZhongYao YaoLi Yu LinChuang, 6 (1990) 33.[11]J. Liu, L. Xia, X.F. Chen. Acta Pharmacol. Sin., 9 (1988) 395[12]H.J. Li, P. Li, W.C. Ye, J. Chromatogr. A 1008(2003) 167-72.[13]Q. Mao, D. Cao, X.SH. Jia. Acta Pharm. Sin., 28(1993) 273.[14]H. Kizu, S. Hirabayashi, M. Suzuki, et al. Chem. Pharm. Bull., 33(1985) 3473.[15]S. Saito, S. Sumita, N. Tamura, et al. Chem Pharm Bull., 38(1990) 411.[16]Alltech ELSD 2000 Operating Manual, Alltech, 2001, p. 16. In Chinese.[17]J.B. Xing, P. Li, Chin. Med. Mater., 22(1999) 366.Fig. 1 Chemical structures of seven saponins from Lonicera confusa macranthoidin B (1), macranthoidin A (2), dipsacoside B (3), hederagenin-28-O-β-D-glucopyranosyl(6→1)-O-β-D- glucopyranosyl ester (4), macranthoside B (5), macranthoside A (6), and hederagenin-3-O-α-L-arabinopyranosyl(2→1)-O-α-L-rhamnopyranoside (7)Fig. 2Representative HPLC chromatograms of mixed standards and methanol extracts of Flos Lonicerae.Column: Agilent Zorbax SB-C18 column（250 4.6mm, 5.0µm）, temperature of 25℃; Detector: ELSD, drift tube temperature 106℃, nitrogen flow-rate 2.6 l/min.A: Mixed standards, B: L. confusa, C: L. japonica, D: L. macranthoides, E: L. hypoglauca, F: L. similes.Table 1 Calibration curves for seven saponinsAnalytes Calibration curve ar2Test range(μg)LOD(μg)LOQ(μg)1 y=6711.9x－377.6 0.9940 0.56–22.01 0.26 0.882 y=7812.6x－411.9 0.9922 0.54–21.63 0.26 0.843 y=6798.5x－299.0 0.9958 0.46–18.42 0.22 0.724 y=12805x－487.9 0.9961 0.38–15.66 0.10 0.345 y=4143.8x－88.62 0.9989 0.42–16.82 0.18 0.246 y=3946.8x－94.4 0.9977 0.40–16.02 0.16 0.207 y=4287.8x－95.2 0.9982 0.42–16.46 0.12 0.22a y: Peak area; x: concentration (mg/ml)Table 2 Reproducibility of the assayAnalyteIntra-day variability Inter-day variability Content (mg/g) Mean RSD (%) Content (mg/g) Mean RSD (%)1 46.1646.2846.2246.22 0.1346.2245.3647.4226.33 2.232 5.385.385.165.31 2.405.285.345.045.22 3.043 4.374.304.184.28 2.244.284.464.024.255.204 nd1)-- -- nd -- --5 1.761.801.821.79 1.701.801.681.841.77 4.706 1.281.241.221.252.451.241.341.201.26 5.727 tr2)-- -- tr -- -- 1): not detected; 2): trace. RSD (%) = (SD/Mean) ×100%Table 3 Recovery of the seven analytesAnalyteOriginal(mg) Spiked(mg)Found(mg)Recovery(%)Mean(%)RSD(%)1 23.0823.1423.1119.7122.8628.1042.7346.1351.0199.7100.699.399.8 0.722.692.672.582.082.913.164.735.515.7698.197.6100.698.8 1.632.172.152.091.732.182.623.884.404.6598.8103.297.799.9 2.94nd1)1.011.050.980.981.101.0297.0104.8104.1102.0 4.250.880.900.910.700.871.081.561.752.0197.197.7101.898.9 2.660.640.620.610.450.610.751.081.211.3397.796.796.096.8 0.97tr2)1.021.101.081.031.111.07100.9102.799.1100.9 1.81): not detected; 2): trace.a Recovery (%) = (Amount found –Original amount)/ Amount spiked ×100%, RSD (%) = (SD/Mean) ×100%Table 4 Contents of seven saponins in Lonicera spp.Content (mg/g)1 2 3 4 5 6 7 L. confusa45.65±0.32 5.13±0.08 4.45±0.11tr1) 2.04±0.04tr 1.81±0.03 L. japonica nd2)nd 3.44±0.09nd nd nd nd L. macranthoides46.22±0.06 5.31±0.13 4.28±0.10 tr 1.79±0.03 1.25±0.03 tr L. hypoglauca11.17±0.07 nq3)53.78±1.18nd 1.72±0.02 2.23±0.06 2.52±0.04 L. similes41.22±0.25 4.57±0.07 3.79±0.09nd 1.75±0.02tr nd 1): trace; 2): not detected.. 3) not quantified owing to the suspicious purity of the peak.。
高效液相色谱法快速检测单胺类神经递质及其代谢产物(英文)
高效液相色谱法快速检测单胺类神经递质及其代谢产物(英文)伦立民;车琳杰;李世伟【期刊名称】《中国临床康复》【年(卷),期】2006(10)22【摘要】背景:单胺类神经递质及其代谢产物对实验研究帕金森病和实验诊断嗜铬细胞瘤具有重要意义,是当今的研究热点。
目的:建立高效液相色谱法同时快速测定肾上腺素、去甲肾上腺素、多巴胺、5-羟色胺、5-羟吲哚乙酸、高香草酸及多巴柯7种单胺类神经递质及其代谢产物。
设计:病例-对照观察和随机对照动物实验。
单位:青岛大学医学院附属医院检验科及青岛大学医学院附属医院海阳分院。
对象:实验于2003-10/12在青岛大学医学院生理教研室和青岛大学医学院附属医院检验科完成。
①2例嗜铬细胞瘤患者,均经CT,MRI或病理切片和临床证实为该病。
12例正常对照均为在校大学生,且经查排除高血压、内分泌系统疾病和其他疾病。
②选用健康雌性Wistar大白鼠12只,体质量150～180g。
随机数字表法分为2组,正常对照组和帕金森病组,每组大鼠各6只。
方法:制备7种物质样品(肾上腺素、去甲肾上腺素、多巴胺、5-羟色胺、5-羟吲哚乙酸、高香草酸及多巴柯)的标准色谱图,同时进行样品精密度和回收率的检测。
采用高效液相色谱法检测12例正常对照和2例嗜铬细胞瘤患者24h尿中的儿茶酚胺类物质。
同时以6-羟基多巴胺损毁帕金森病组大鼠大脑一侧前脑束,以监测正常和帕金森病大鼠健侧及损毁侧尾壳核区纹状体内单胺类神经递质及其代谢产物的释放特点。
主要观察指标:①样品精密度和回收率检测结果。
②12例正常对照和2例嗜铬细胞瘤患者24h尿中儿茶酚胺类物质的测定结果。
③各组大鼠纹状体内单胺类神经递质及其代谢产物的释放特点。
结果:12例正常对照和2例嗜铬细胞瘤患者均获得24h尿中儿茶酚胺类物质检测结果,并进入结果分析。
实验动物在实验中无死亡。
①高效液相色谱法对肾上腺素、去甲肾上腺素、多巴胺、5-羟色胺、5-羟吲哚乙酸、高香草酸及多巴柯7种单胺类物质的线性范围为2～1000μg/L,最低检测限为2～30μg/L,批内精密度为3.0%～8.6%,批间精密度为3.8%～9.7%。
AMI-1_DataSheet_MedChemExpress
Inhibitors, Agonists, Screening Libraries Data SheetBIOLOGICAL ACTIVITY:AMI–1 is a potent, cell–permeable compound which inhibits protein arginine N–methyltransferases (PRMTs), including human PRMT1(IC50 = 8.8μM) and yeast–Hmt1p (IC50 = 3.0μM), by blocking peptide–substrate binding.IC50 value: 8.8μM (human PRMT1), 3.0μM (yeast–Hmt1p)Target: human PRMT1, yeast–Hmt1pin vitro: AMI–1 suppresses the transcriptional coactivator activity of PRMT1 and PRMT4 and it inhibits HIV–1 RT polymerase (IC50 =5.0μM). PRMT1 methylates histone H4, and is essential for other subsequent histone modifications.[1] AMI–1 is the most active nonpeptidic inhibitor reported to be selective against PRMT1. AMI–1 is a selective PRMT inhibitor with a bisanionic structure that is related to compounds known to generate pleiotropic interactions with many proteins, should be further optimized before exploring additional binding pockets. [2]in vivo: AMI–1 is administered intranasally to chronic AIPI rats to determine PRMT effects on asthmatic parameters. AMI–1 inhibited the expression of COX2 in TGF–β–stimulated cells. AMI–1 administered to AIPI rats reduced COX2 production and humoral immune response, and it abrogated mucus secretion and collagen generation.[1]PROTOCOL (Extracted from published papers and Only for reference)Cell assay [3]INS–1 cells were grown in a humidified atmosphere containing 95 % air and 5 % CO2 in RPMI–1640 medium containing 11.1 mM glucose, 10 % FBS, 1 mM pyruvate, 10 mM HEPES, 50 lM 2–mercaptoethanol, 100 U/mL penicillin, and 100 lg/mL streptomycin. Cells were then transfected with siPRMT1 or the indicated plasmid, and subsequently cultured in RPMI–1640 medium containing 5.6 or 25mM glucose (5.6 G and 25 G, respectively) and/ or 100 lM AMI–1. For transfection with siPRMT1 (target sequence50–CCAACGCCTGCCTCATAAA–30) or pALTER– FOXO1, INS–1 cells grown in 6–well plates were transfected using Lipofectamine 2000,and the media were replaced 6 h after transfection. Seventy–two hours after transfection, the cells were treated with 25 mM glucose and/or AMI–1 (100 lM) for an additional 48 h, and then harvested for the assays described below.Animal administration [1]For the AMI–1 treatment experiment, 24 rats were divided into three groups: control group, chronic AIPI group, and AMI–1 group.Two weeks after sensitization, control group rats were sham sensitized and exposed to the same volume of PBS. In the AMI–1 group,rats were administered 50μl AMI–1 at a concentration of 0.1 mg/ml in PBS 2 h before OVA challenge. The asthma index included serum levels of OVA–specific IgG1 and total serum IgE, which were determined by ELISA as described in previous studies.References:Product Name:AMI–1Cat. No.:HY-18962CAS No.:20324-87-2Molecular Formula:C 21H 14N 2Na 2O 9S 2Molecular Weight:548.45Target:Histone Methyltransferase Pathway:Epigenetics Solubility:DMSO: ≥ 46 mg/mL[1]. Sun Q, et al. PRMT1 Upregulated by Epithelial Proinflammatory Cytokines Participates in COX2 Expression in Fibroblasts and Chronic Antigen–Induced Pulmonary Inflammation. J Immunol. 2015 Jul 1;195(1):298–306.[2]. Castellano S, et al. Design, synthesis and biological evaluation of carboxy analogues of arginine methyltransferase inhibitor 1 (AMI–1). ChemMedChem. 2010 Mar 1;5(3):398–414.[3]. Lv L, et al. PRMT1 promotes glucose toxicity–induced β cell dysfunction by regulating the nucleo–cytoplasmic trafficking of PDX–1 in aFOXO1–dependent manner in INS–1 cells. Endocrine. 2015 Aug;49(3):669–682.[4]. Wang J, et al. Pharmacophore–based virtual screening and biological evaluation of small molecule inhibitors for protein arginine methylation. J Med Chem. 2012 Sep 27;55(18):7978–7987.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
AR-A014418_DataSheet_MedChemExpress
Inhibitors, Agonists, Screening Libraries Data SheetBIOLOGICAL ACTIVITY:AR–A014418 is a selective and effective GSK3β inhibitor with an IC 50 value of 104 nM, and has no significant inhibition on 26 other kinases.IC50 & Target: IC50: 104 nM (GSK3β)In Vitro: AR–A014418 inhibits tau phosphorylation at a GSK3–specific site (Ser–396) in 3T3 fibroblasts expressing human four–repeat tau protein with IC 50 of 2.7 μM, and protects cultured N2A cells from death induced by blocking PI3K/PKB pathway. In hippocampal slices, AR–A014418 inhibits neurodegeneration mediated by beta–amyloid peptide [1]. While in NGP and SH–5Y–SY cells,AR–A014418 reduces neuroendocrine markers and suppresses neuroblastoma cell growth [2].In Vivo: In ALS mouse model with the G93A mutant human SOD1, AR–A014418 (0–4 mg/kg, i.p.) delays the onset of symptoms,improves motor activity, slows down disease progression, and postpons the endpoint of the disease [3]. In addition, AR–A014418produces inhibition effect on acetic acid– and formalin–induced nociception in mice by modulating NMDA and metabotropic receptor signaling as well as TNF–α and IL–1β transmission in the spinal cord [4].PROTOCOL (Extracted from published papers and Only for reference)Kinase Assay:[1]The competition experiments are carried out in duplicate with 10 concentrations of the inhibitor inclear–bottomed microtiter plates. The biotinylated peptide substrate, biotin–AAEELDSRAGS(PO3H2)PQL, is added at a final concentration of 2 μM in an assay buffer containing 6 milliunits of recombinant human GSK3 (equal mix of both α and β), 12mM MOPS, pH 7.0, 0.3 mM EDTA, 0.01% β–mercaptoethanol, 0.004% Brij 35, 0.5% glycerol, and 0.5 μg of bovine serumalbumin/25 μL and preincubated for 10–15 min. The reaction is initiated by the addition of 0.04 μCi of [γ–33P]ATP and unlabeled ATP in 50 mM Mg(Ac)2 to a final concentration of 1 μM ATP and assay volume of 25 μL. Blank controls without peptide substrate are used.After incubation for 20 min at room temperature, each reaction is terminated by the addition of 25 μL of stop solution containing 5mM EDTA, 50 μM ATP, 0.1% Triton X–100, and 0.25 mg of streptavidin–coated SPA beads corresponding to appr 35 pmol of binding capacity. After 6 h the radioactivity is determined in a liquid scintillation counter. Inhibition curves are analyzed by non–linear regression using GraphPad Prism.Cell Assay: AR–A014418 is dissolved in DMSO.[1]Cell viability is assessed by calcein/propidium iodide uptake. Calcein AM is taken up and cleaved by esterases present within living cells, yielding yellowish–green fluorescence, whereas PI is only taken up by dead cells,which become orange–red fluorescent. In brief, N2A cells are cultured for 2 days in vitro and then treated with 50 μM LY–294002 in the presence of AR–A014418 or vehicle (DMSO) for 24 h. Subsequently, N2A cells are incubated for 30 min with 2 μM PI and 1 μM calcein–AM. The cultures are then rinsed three times with Hanks' buffered saline solution containing 2 mM CaCl 2, and the cells are visualized by fluorescence microscopy using a Zeiss Axiovert 135 microscope. Three fields (selected at random) are analyzed per well (appr 300 cells/field) in at least three different experiments. Cell death is expressed as percentage of PI–positive cells from the total number of cells. In every experiment, specific cell death is obtained after subtracting the number of dead cells present inProduct Name:AR–A014418Cat. No.:HY-10512CAS No.:487021-52-3Molecular Formula:C 12H 12N 4O 4S Molecular Weight:308.31Target:GSK–3; GSK–3Pathway:Stem Cell/Wnt; PI3K/Akt/mTOR Solubility:10 mM in DMSOvehicle–treated cultures.Animal Administration: AR–A014418 is formulated in normal saline.[3]First, to examine the effects of GSK–3 inhibition on the clinical symptoms, life span, and motor behavior function of ALS, 56 Tg mice are divided into four groups. In each group, 0.5 mL of normal saline is mixed with either 0 μg (control group), 1 μg (group A), 2 μg (group B) or 4 μg (group C) of AR–A014418 per gram of mouse, and injected intraperitoneally into 14 animals per group 5 days a week beginning 60 days after birth. The mice are sacrificed at the endpoint described below.References:[1]. Bhat R, Xue Y, Berg S, Structural insights and biological effects of glycogen synthase kinase 3–specific inhibitor AR–A014418. J Biol Chem. 2003 Nov 14; 278(46):45937–45.[2]. Carter YM, et al. Specific glycogen synthase kinase–3 inhibition reduces neuroendocrine markers and suppresses neuroblastoma cell growth. Cancer Biol Ther. 2014 May;15(5):510–5.[3]. Koh SH, et al. Inhibition of glycogen synthase kinase–3 suppresses the onset of symptoms and disease progression of G93A–SOD1 mouse model of ALS. Exp Neurol. 2007 Jun;205(2):336–46.[4]. Martins DF, et al. The antinociceptive effects of AR–A014418, a selective inhibitor of glycogen synthase kinase–3 beta, in mice. J Pain. 2011 Mar;12(3):315–22.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
用于到达派亚氏淋巴结的口服生物活性剂的制法和配方[发明专利]
![用于到达派亚氏淋巴结的口服生物活性剂的制法和配方[发明专利]](https://img.taocdn.com/s3/m/280882c5192e45361166f512.png)
专利名称：用于到达派亚氏淋巴结的口服生物活性剂的制法和配方
专利类型：发明专利
发明人：T·R·泰斯,J·K·斯泰斯,R·M·吉利,J·H·埃尔德里奇
申请号：CN95100893.5
申请日：19880409
公开号：CN1111157A
公开日：
19951108
专利内容由知识产权出版社提供
摘要：本发明有关口服生物活性剂的方法和配方，这生 物活性剂包括将活性剂在一种或多种可生物降解和 生物相容的聚合物或共聚物赋形剂中胶囊化以形成 微胶囊。
这种微胶囊能够不受影响的通过胃肠道且 被派亚氏淋巴结所吸收。
申请人：南方研究所,UAB研究基金会
地址：美国阿拉巴马州
国籍：US
代理机构：中国专利代理(香港)有限公司
代理人：姜建成
更多信息请下载全文后查看。
Erythrosin_B_SDS_MedChemExpress
Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:Jan.-22-2018Print Date:Jan.-22-20181. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :Erythrosin BCatalog No. :HY-D0259CAS No. :16423-68-01.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureGHS Classification in accordance with 29 CFR 1910 (OSHA HCS)Acute toxicity, Oral (Category 4), H302Chronic aquatic toxicity (Category 4), H4132.2 GHS Label elements, including precautionary statementsPictogramSignal word WarningHazard statement(s)H302 Harmful if swallowed.H413 May cause long lasting harmful effects to aquatic life.Precautionary statement(s)P264 Wash skin thoroughly after handling.P270 Do not eat, drink or smoke when using this product.P273 Avoid release to the environment.P301 + P312 + P330 IF SWALLOWED: Call a POISON CENTER ⁄doctor if you feel unwell.Rinse mouth.P501 Dispose of contents ⁄ container to an approved waste disposal plant.H413 May cause long lasting harmful effects to aquatic life.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:Erythrosin extra bluishFormula:C20H6I4Na2O5Molecular Weight:879.86CAS No. :16423-68-04. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Powder-20°C 3 years4°C 2 yearsIn solvent-80°C 6 months-20°C 1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance Pink to red (Solid)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2017 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
Litronesib_NP-HPLC_19488_MedChemExpress
============================================================================================Acq. Operator :CSS(HPLC-10)Seq. Line :4Acq. Instrument :Instrument 1Location :Vial 38Injection Date :2016-02-0409:44:26Inj :1Inj. Volume :5 µlD:\CHEM\DATA\20160204\20160204 2016-02-04 08-45-54\OD,90B-ETOH,210NM,C2.MAnalysis Method : D :\CHEM\.M\BLAY,80A-ETOH,210NM(HM-392_7).M C-NP-16 ->min02468101214mAU-2000200400 VWD1 A, Wavelength=210 nm (20160204\20160204 2016-02-04 08-45-54\038-0401.D)7.0128.070min2468101214mAU010203040 VWD1 A, Wavelength=210 nm (20160204\20160204 2016-02-04 08-45-54\038-0401.D) 7.0128.070Signal:VWD1 A, Wavelength=210 nmRetTime Width PlatesHeight Tail Resolution Area Area Name [min][min][mAU*s]%-------|---------|---------|-------|------|---------|----------|--------|------- 7.0100.188859 1.25 1.65 8.730.065 8.0700.422013501.43 2.00 2.0813375.1599.935 Total:13383.881============================================================================================*** (QG RI 5HSRUW ***Data File: D:\CHEM\DATA\20160204\20160204 2016-02-04 08-45-54\038-0401.D Sample Name: HYQ3145-060-1Page 1/1Catalog No : HY-14846 Batch#19488=====================================================================Acq. Operator : CSS(HPLC-10) Seq. Line : 3Acq. Instrument : Instrument 1 Location : Vial 36Injection Date : 2016-02-04 09:27:55 Inj : 1Inj Volume : 5.000 µlAcq. Method : D:\CHEM\DATA\20160204\20160204 2016-02-04 08-45-54\OD,90B-ETOH,210NM,C2.M Last changed : 2016-02-04 09:33:24 by CSS(HPLC-10) (modified after loading)A nalysis Method : D:\CHEM\.M\BLAY,80A-ETOH,210NM(HM-392_7).M Last changed : 2016-02-04 10:17:57 by CSS(HPLC-10) (modified after loading)Catalog No : HY-14846 Batch#19488 C-NP-16Additional Info : Peak(s) manually integratedmin2468101214mAU -50050100150200250 VWD1 A, Wavelength=210 nm (20160204\20160204 2016-02-04 08-45-54\036-0301.D)===================================================================== Area Percent Report =====================================================================Sorted By : SignalMultiplier: : 1.0000Dilution: : 1.0000Use Multiplier & Dilution Factor with ISTDsNo peaks found===================================================================== *** End of Report ***Data File D:\CHEM\DATA\20160204\20160204 2016-02-04 08-45-54\036-0301.D Sample Name: HYQ3145-060-1_0Instrument 1 2016-02-04 10:18:00 CSS(HPLC-10)Page 1 of 1============================================================================================Acq. Operator :CSS(HPLC-10)Seq. Line :5Acq. Instrument :Instrument 1Location :Vial 37Injection Date :2016-02-0410:00:59Inj :1Inj. Volume :5 µlD:\CHEM\DATA\20160204\20160204 2016-02-04 08-45-54\OD,90B-ETOH,210NM,C2.MAnalysis Method : D :\CHEM\.M\BLAY,80A-ETOH,210NM(HM-392_7).M C-NP-16 ->min02468101214mAU -300-200-1000100 VWD1 A, Wavelength=210 nm (20160204\20160204 2016-02-04 08-45-54\037-0501.D)7.0408.226min2468101214mAU010203040 VWD1 A, Wavelength=210 nm (20160204\20160204 2016-02-04 08-45-54\037-0501.D)7.0408.226Signal:VWD1 A, Wavelength=210 nmRetTime Width PlatesHeight Tail Resolution Area Area Name [min][min][mAU*s]%-------|---------|---------|-------|------|---------|----------|--------|------- 7.0400.322710189.99 1.47 3938.0349.700 8.2300.362840171.93 1.49 2.043985.6250.300 Total:7923.646============================================================================================*** (QG RI 5HSRUW ***Data File: D:\CHEM\DATA\20160204\20160204 2016-02-04 08-45-54\037-0501.D Sample Name: HYQ3145-060-1_RSPagPage 1/1Catalog No : HY-14846 Batch#19488。
甘油分解代谢缺陷型大肠杆菌菌株中的丝氨醇生产[发明专利]
![甘油分解代谢缺陷型大肠杆菌菌株中的丝氨醇生产[发明专利]](https://img.taocdn.com/s3/m/ef50ccde0b4c2e3f56276332.png)
专利名称：甘油分解代谢缺陷型大肠杆菌菌株中的丝氨醇生产专利类型：发明专利
发明人：L·马克西姆,A·施泰因比歇尔,B·安德森
申请号：CN201380047177.0
申请日：20130904
公开号：CN104769105A
公开日：
20150708
专利内容由知识产权出版社提供
摘要：本发明涉及能够将甘油转化成丝氨醇的大肠杆菌宿主细胞。
另外，公开了一种用于产生丝氨醇的方法，所述方法包括培养无磷酸丙糖异构酶活性和有磷酸二羟丙酮氨基转移酶活性的大肠杆菌宿主细胞以将甘油转化成丝氨醇，通过向细胞培养物至少添加甘油诱导从甘油转化成丝氨醇，和从细胞培养物分离丝氨醇。
申请人：巴斯夫欧洲公司
地址：德国路德维希港
国籍：DE
代理机构：北京市中咨律师事务所
更多信息请下载全文后查看。
栅列藻蛋白质提取液促进人子宫颈癌细胞的生长研究
栅列藻蛋白质提取液促进人子宫颈癌细胞的生长研究
黄文栋;钱凯先
【期刊名称】《浙江大学学报：自然科学版》
【年(卷),期】1997(031)001
【摘要】本文采用ＭＴＴ快速微量比色技术发现斜生栅列藻蛋白质提取液可促进动物细胞的生长。
在０．５％以牛血清的ＲＰＭＩ１６４０培养液中，加入９５μｇ／ｍｌ栅列藻提取液中可使人子宫颈癌细胞比对照组细胞增殖３倍左右。
【总页数】7页(P65-71)
【作者】黄文栋;钱凯先
【作者单位】浙江大学生物科学与技术系;浙江大学生物科学与技术系
【正文语种】中文
【中图分类】R737.33
【相关文献】
1.酚类、醇类抑制斜生栅列藻生长的毒性效应 [J], 高为;沈云;程鑫
2.表皮生长因子对人子宫颈癌细胞形态及噻唑蓝还原的影响 [J], 陈新志;洪新;陈知航;卢永科;仲来福
3.鞭枝藻与其突变体提取液对人膀胱癌细胞生长的影响 [J], 钱凯先;Sato,GH
4.二氧化碳联合核桃壳提取液促进单针藻Monoraphidium sp.QLZ-3的生长和油脂积累 [J], 邢海亮; 董训赞; 韩本勇; 耿树香; 宁德鲁; 马婷; 余旭亚
5.天花粉多糖促人外周血单个核细胞增殖和对人乳腺癌细胞人子宫颈癌细胞的生长抑制作用 [J], 赵桂珠;朱逢佳;徐水凌;曹丽莉;唐文稳
因版权原因，仅展示原文概要，查看原文内容请购买。